-
New drug for ulcerative colitis (UC)! 4-year data from the Stelara Phase 3 study: Sustained symptom relief & corticosteroid-free relief!
Time of Update: 2022-11-01
STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis Stelara has been approved in China for 2 indications: plaque psoriasis and Crohn's disease.
-
New drug for rare liver diseases! EU CHMP recommends approval of Livmarli: Treatment of cholestatic itching associated with Alagille syndrome (ALGS)!
Time of Update: 2022-11-01
Recently, the company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review recommending the approval of Livmarli (maralixibat) oral solution: the drug is taken orally once daily for the treatment of cholestatic pruritus in patients older than 2 months of age with Alagille syndrome (ALGS).
-
A 2022 Autumn Opening Ceremony, allowing you to face the grand event of the environmental protection industry online!
Time of Update: 2022-10-31
Real-time sharing, current affairs discussion, in this SEE, in this SEE Summit Forum, starting from the opening ceremony of SEEC, we are invited to come!【Pharmaceutical Network Exhibition Report】The 2022 Autumn Exhibition of the Sight Environment Expo is about to start, and no one will know this news, right?
-
Pueraria mirifica extract puerarin 98% Pueraria flavonoids 40% Xi'an Quercus Ping Biological Industry News
Time of Update: 2022-10-31
Puerara mirifica extract 98% Pueraria mirifica flavonoids 40% Xi'an Quercus Ping Biological Industry News 【Product Name】:Pueraria Mirifica Extract 【English name】:P ueraria extract 【Active ingredient】
-
In the first three quarters, the R&D expenditure of many pharmaceutical companies increased significantly, and the innovation results were fruitful
Time of Update: 2022-10-31
For example, Chinese medicine company Yiling Pharmaceutical released its third quarterly report on the evening of October 27, in the first three quarters, the company's R&D expenses were 552 million yuan, and the R&D expense rate increased by 2.
-
Antidepressant TOP10 reshuffle Green leaf class 1 new drugs are eye-catching
Time of Update: 2022-10-31
0 China Drug Evaluation Database Since the beginning of this year, 6 varieties (27 specifications) of antidepressants have been approved for marketing, among which escitalopram oxalate tablets, mirtazapine tablets, venlafaxine hydrochloride sustained-release capsules, and duloxetine hydrochloride enteric-coated capsules are the terminal TOP10 products in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in the first half of 2022.
-
The research and development of innovative drugs in China has ushered in a harvest period, but it is also facing new challenges
Time of Update: 2022-10-31
In the past two years, affected by a series of favorable policies, capital increase and other factors, the enthusiasm for the research and development of domestic innovative drugs has been high, and it has gradually entered the harvest period.
-
The shoot dry market broke through the all-time high, can it continue to go higher in the future?
Time of Update: 2022-10-31
Shooting dry is one of the star varieties in the Chinese herbal medicine market in the past two years, and the price of Hebei Tong has risen from 29 yuan (kg price, the same below) in January 2021 to
-
The cost of raw materials such as windbreak soared, and the profit of Zhongsheng Pharmaceutical fell!
Time of Update: 2022-10-31
According to data from Intranet, the total sales of Zhongsheng Pharmaceutical's compound thrombosis in the three major terminals in 2021 reached 860 million yuan, and in the market of proprietary Chinese medicine for heat clearing and detoxification, the total sales of Zhongsheng series products in the three major terminals in 2020 also exceeded 100 million yuan.
-
The legendary creature CAR-T sells well in Europe and the United States! Domestic CAR-T is still involutional! "Going to sea" through the winter?
Time of Update: 2022-10-31
October 2017 Targeting CD19 The FDA approved Gilead's Yescarta for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) who have previously received second- or multi-line systemic therapy.
-
After the sixth batch of insulin collection landed, the winning pharmaceutical company actively expanded production and transformation
Time of Update: 2022-10-31
Winning pharmaceutical companies actively expand production and transformation After the landing of centralized procurement, coupled with the continuous expansion of market demand for insulin, insufficient production capacity has become a problem faced by winning enterprises.
-
The National Center for Critical Care Medicine and the National Center for Critical Care Regional Medical Centers set standards
Time of Update: 2022-10-31
Health Commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to implement the decisions a
-
Luteolin 98% Quercus Organism Supply Peanut Shell Extract Industry Dynamics
Time of Update: 2022-10-31
Luteolin 98% Quercus Ping Biological Supply Peanut Shell Extract Industry Dynamic Company Xi'an Liping Biotechnology Co.
Luteolin 98% Quercus Ping Biological Supply Peanut Shell Extract Industry Dynamic Company Xi'an Liping Biotechnology Co.
Luteolin 98% Quercus Ping Biological Supply Peanut Shell Extract Industry Dynamic Company Xi'an Liping Biotechnology Co.
-
State Food and Drug Administration: Announcement on amending the instructions of domperidone preparations
Time of Update: 2022-10-31
） According to the results of adverse drug reaction assessment, in order to further protect the safety of public drug use, the State Medical Products Administration decided to uniformly revise the instructions of domperidone preparations (including domperidone tablets, domperidone dispersible tablets, domperidone oral disintegration tablets, domperidone capsules, domperidone suspension, domperidone maleate tablets).
-
Jiangsu will include the "psychotherapy" project in medical insurance from November 1
Time of Update: 2022-10-31
Jiangsu clarifies the connotation of the "psychotherapy" project, which refers to "psychiatrists who have received standardized psychotherapy training or health technicians who have obtained professional and technical qualifications in psychotherapy, in a suitable independent treatment space, for patients with mental disorders who meet the conditions for psychotherapy, apply standardized psychotherapy techniques and individualized treatment plans to carry out psychotherapy, and eliminate or alleviate the manifestations of patients' psychological disorders.
-
Jinzhong National Agricultural High Zone: Planting small wormwood and developing a large "wormwood" industry
Time of Update: 2022-10-31
” In recent years, Jinzhong National Agricultural High Zone (Taigu National Science and Technology Innovation Center) has vigorously developed organic dry farming and cultivated advantageous industries with traditional Chinese medicinal materials.
-
Neurointerventional consumables spring ring collection: sweeping 21 provinces Resurrection mechanism
Time of Update: 2022-10-31
The selection rules of the 21 provincial spring ring collective procurement alliance are relatively modest A resurrection mechanism exists in both groups of AB From the perspective of the centralized procurement rules of the 21 provinces, the proposed selection rules are quite moderate, and the products are divided into two groups of AB according to the size of the medical institutions.
-
There is a huge demand in the Internet chronic disease management market, and related companies are accelerating their layout
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; In recent years, with the intensification of population aging, a series of supportive policies such as "Opinions on Promoting the Development of "Internet + Medical Health" and "Measures for the Administration of Internet Diagnosis and Treatment", as well as favorable factors such as the improvement of people's medical and health awareness, many pharmaceutical companies and Internet medical platforms are helping the prevention and treatment of chronic diseases by continuously developing chronic disease drugs and actively innovating service models.
-
Novartis antiepileptic drugs under supply pressure? MNC brand drug "Red Sea" is facing a breakthrough!
Time of Update: 2022-10-31
6 billion antiepileptic drugs market The share left for Qu Lai is getting smaller and smaller Developed by Novartis, oxcarbazepine was approved by the US FDA in 2000 and entered the Chinese market in 2004 under the trade name "Qulai".
-
Xi'an Quercus Ping Biology welcome consultation: Cnidium monnieri 10%-98% plant monomer
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Xi'an Quercus Ping Biology Welcome to consult: Cnidium monnieri 10%-98% Plant monomer composition Chinese Name: Cnidium monnieri Chinese synonyms: Cnidium monnieri seed; 7-Methoxy-8-isoprenyl coumarin; Cnidium monnieri (7-methoxy-8-isoprenyl coumarin) English name: Osthole CAS number: 484-12-8 Molecular Formula: C15H16O3 Molecular weight: 244.
